Phase 2 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 40 years of age or older
- People with a body mass index (a measure of body weight relative to height) of 27 or above
- People whose heart is pumping at least 50% of its normal capacity, and who experience mild to moderate heart failure symptoms such as shortness of breath or tiredness with everyday activities
- People who have been diagnosed with a type of heart failure called HFpEF, supported by at least one of the following: a past hospital stay or urgent visit due to HFpEF where fluid-removing medication was given through a drip; an enlarged left chamber of the heart (confirmed by specific measurements); high pressure in the heart detected during a specialised heart test; certain abnormal results on a heart ultrasound; or an elevated level of a specific heart stress marker in the blood (confirm with trial site for exact values)
- People who have completed a specific breathing and exercise test at the start of the trial showing they made a full physical effort during the test
- People who are able to walk independently (not reliant on a wheelchair or scooter) and can complete walking and fitness tests
- People whose medications have been at a stable dose for at least 30 days before the screening visit, with no new medications added and no existing dose changed by 50% or more
Who may not be able to join:
- People who have had a serious worsening of their heart failure in the past 30 days that required hospital admission or intravenous fluid-removing medication
- People who started a certain class of diabetes or weight management medication (GLP-1 receptor agonist or SGLT2 inhibitor) within 60 days before screening
- People who have planned heart surgery or a heart procedure during the trial period
- People who have recently joined or plan to join a weight loss program, cardiac rehabilitation, or a new exercise program during the study
- People with certain specific types of heart muscle disease (such as constrictive, restrictive, infiltrative, toxic, hypertrophic, or congenital cardiomyopathy), or whose heart pumping function was below 40% at any point in the last three years, or who have active inflammation of the heart muscle
- People who are currently breastfeeding, pregnant, or planning to become pregnant
- People with serious conditions affecting other organ systems — such as a lung condition requiring supplemental oxygen at home during the day, severe anaemia (very low red blood cell levels), or advanced kidney disease — where that condition, rather than the heart failure, is considered the main reason for limited exercise ability
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gregory D. Lewis, MD, Massachusetts General Hospital
Phone: 617-724-9254
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in peak oxygen uptake (peak VO2) in HFpEF subjects following activin ligand-trap biological therapy or placebo.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.